Comparative cost-effectiveness of three intrauterine devices: a multi-center randomized trial.

نویسندگان

  • Jin Wen
  • Ying Li
  • Youping Li
  • Li Wang
  • Jian Zhou
  • Lei Ba
  • Suqi Shen
  • Yulin Wu
چکیده

OBJECTIVE To determine the relative cost-effectiveness of three intrauterine devices (IUDs), MLCu375, TCu380A, and YuangongCu365. METHODS Cost-effectiveness of three IUDs, namely MLCu375, TCu380A, and YuangongCu365, was analyzed from the provider's perspective by means of a randomized trial with one-year follow-up carried out in six centers in China. RESULTS YuangongCu 365 had the lowest termination and pregnancy rates (4.17% and 0.54%, respectively), followed by TCu380A (8.59% and 1.11%, respectively) and MLCu375 (14.17% and 2.04%, respectively). YuangongCu365 was more effective yet more costly than the MLCu375. There was a favorably dominating trend of cost-effectiveness for TCu380A comparing with MLCu375 when taking continuation rate as the effectiveness indicator, but there was no difference in cost-effectiveness between the two IUDs when using the pregnancy avoidance rate as the effectiveness measure. CONCLUSIONS TCu380A is slightly more cost-effective than the MLCu375. YuangongCu365 is the most effective of the three devices and be used provided it is economically affordable. The comparative long-term safety and cost-effectiveness of these devices need to be further investigated.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™) and Activated Prothrombin Complex Concentrates (FEIBA™) to Treat Hemophilia A Patients with Inhibitors in Iran

Abstract Nowadays, bypassing agents such as recombinant activated factor VII (rFVIIa) and activated prothrombin complex concentrates (aPCC) are used to treat bleeding episodes in the Hemophilia patients with inhibitors. AryoSeven® is an Iranian biogeneric rFVIIa with homogeneity of efficacy and the nature to NovoSeven in a comparative trial. The current clinical trial aimed to evaluate the cost...

متن کامل

Cost-Effectiveness Analysis of Biogeneric Recombinant Activated Factor VII (AryoSeven™) and Activated Prothrombin Complex Concentrates (FEIBA™) to Treat Hemophilia A Patients with Inhibitors in Iran

Abstract Nowadays, bypassing agents such as recombinant activated factor VII (rFVIIa) and activated prothrombin complex concentrates (aPCC) are used to treat bleeding episodes in the Hemophilia patients with inhibitors. AryoSeven® is an Iranian biogeneric rFVIIa with homogeneity of efficacy and the nature to NovoSeven in a comparative trial. The current clinical trial aimed to evaluate the cost...

متن کامل

O-32: Effects of Intrauterine Injection of Recombinant Human Chorionic Gonadotropin before Embryo Transfer on Outcome of In Vitro Fertilization/Intracytoplasmic Sperm Injection: A Randomized Clinical Trial

Background: To evaluate the effectiveness of intrauterine injection of recombinant human chorionic gonadotropin (rhCG) before embryo transfer (ET). Materials and Methods: In this randomized placebocontrolled clinical trial, a total number of 182 infertile patients undergoing their first in vitro fertilization/intracytoplasmic sperm injection (IVF-ICSI) were randomly assigned to receive 250 μg i...

متن کامل

A randomized clinical trial to evaluate optimal treatment for unexplained infertility: the fast track and standard treatment (FASTT) trial.

OBJECTIVE To determine the value of gonadotropin/intrauterine insemination (FSH/IUI) therapy for infertile women aged 21-39 years. DESIGN Randomized controlled trial. SETTING Academic medical center associated with a private infertility center. PATIENT(S) Couples with unexplained infertility. INTERVENTION(S) Couples were randomized to receive either conventional treatment (n=247) with t...

متن کامل

Assessing the comparative effectiveness of Tai Chi versus physical therapy for knee osteoarthritis: design and rationale for a randomized trial

BACKGROUND Knee osteoarthritis (OA) causes pain and long-term disability with annual healthcare costs exceeding $185 billion in the United States. Few medical remedies effectively influence the course of the disease. Finding effective treatments to maintain function and quality of life in patients with knee OA is one of the national priorities identified by the Institute of Medicine. We are cur...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:
  • Journal of evidence-based medicine

دوره 3 2  شماره 

صفحات  -

تاریخ انتشار 2010